Abstract
Data from the phase III ENHANCE clinical trials provide compelling evidence that ensifentrine, an inhaled ‘bifunctional’ dual phosphodiesterase 3/4 inhibitor, can provide additional benefit to exis... Plain language summary Chronic obstructive pulmonary disease (COPD) is the name for a group of lung conditions that cause breathing difficulties/airflow limitations. The airflow limitation is not c... Tweetable abstract Ensifentrine, an inhaled ‘bifunctional’ dual PDE3/4 inhibitor, can provide additional benefit to existing treatments in patients with COPD and represents a ‘first in class’ drug ...
Funding Information
  • Verona Pharma (9717732, 9700558, 20160008363, 20160000790, 20170266190)

This publication has 30 references indexed in Scilit: